<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611386</url>
  </required_header>
  <id_info>
    <org_study_id>Bursa Yüksek İhtisas EAH</org_study_id>
    <nct_id>NCT04611386</nct_id>
  </id_info>
  <brief_title>The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors</brief_title>
  <official_title>Bursa Postgraduate Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Postgraduate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Postgraduate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of iohexol as a contrast agent on the&#xD;
      anticoagulant activity of oral factor Xa inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included 65 people who underwent contrast computerized tomography (CT). The study&#xD;
      patients were divided into 4 groups. Patients in group 1 were using rivaroxaban (20&#xD;
      patients), patients in group 2 were using apixaban (20 patients), patients in group 3 were&#xD;
      using edoxaban (20 patients), and group 4 was the control group (5 volunteers). Iohexol (60&#xD;
      ml) was used as a contrast agent. Two tubes were used to collect 2 ml of blood from the&#xD;
      patients at 4 hours after the drug dose (rivaroxaban, apixaban, or edoxaban) and 1 hour after&#xD;
      the contrast CT (CT was performed 3 hours after the drug was taken). In the control group, at&#xD;
      any time and 1 hour after contrast CT, 2 tubes of 2 ml of blood were collected. The&#xD;
      anticoagulant properties of rivaroxaban, apixaban, and edoxaban were evaluated using&#xD;
      anti-factor Xa levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Days</target_duration>
  <primary_outcome>
    <measure>Anti Factor Xa level</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Contrast Agents and Oral Factor Xa Inhibitor</condition>
  <arm_group>
    <arm_group_label>rivaroxaban group</arm_group_label>
    <description>20 rivaroxaban using patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apixaban group</arm_group_label>
    <description>20 apixaban using patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>edoxaban group</arm_group_label>
    <description>20 edoxaban using patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>5 control group patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>computerized tomography</intervention_name>
    <description>Anti Factor Xa level</description>
    <arm_group_label>apixaban group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>edoxaban group</arm_group_label>
    <arm_group_label>rivaroxaban group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study prospectively included 65 people who underwent contrast computerized tomography&#xD;
        (CT). The CT indications were thoracic aortic dilatation, chronic obstructive pulmonary&#xD;
        disease, abdominal aortic dilatation, chronic abdominal pain.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. the use of oral factor Xa inhibitors (patients with nonvalvular AF and CHA2DS2-VASc&#xD;
             Score ≥2),&#xD;
&#xD;
          2. age of 21-80 years,&#xD;
&#xD;
          3. no contraindications for anticoagulation use,&#xD;
&#xD;
          4. GFR greater than 30,&#xD;
&#xD;
          5. volunteering to participate in the study, and&#xD;
&#xD;
          6. patients who needed to use contrast agent (iohexol) for CT examination. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. coagulopathy,&#xD;
&#xD;
          2. severe hepatic insufficiency,&#xD;
&#xD;
          3. chronic systemic or inflammatory diseases,&#xD;
&#xD;
          4. patients lighter than 60 kg,&#xD;
&#xD;
          5. malignancy,&#xD;
&#xD;
          6. creatinine value above 1.5 mg/dl, and&#xD;
&#xD;
          7. not providing consent to participate in the study -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Postgraduate Hospital</investigator_affiliation>
    <investigator_full_name>Hasan ARI</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

